Prevention of malignant hypertension by the synthetic peptide SQ 20,881.
D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D000818:Animals; D001158:Arteries / Q000473:pathology; D001769:Blood; D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D001920:Bradykinin / Q000494:pharmacology; D002245:Carbon Dioxide / Q000097:blood; D003106:Colon / Q000473:pathology; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D004357:Drug Synergism; D006863:Hydrogen-Ion Concentration; D006974:Hypertension, Malignant / Q000473:pathology / Q000517:prevention & control*; D006977:Hypertension, Renal; D007273:Injections, Intramuscular; D007413:Intestinal Mucosa / Q000098:blood supply / Q000473:pathology; D007421:Intestine, Small / Q000473:pathology; D007679:Kidney Medulla / Q000166:cytology / Q000637:transplantation; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage*; D011817:Rabbits; D012078:Renal Artery Obstruction; D013997:Time Factors; D014182:Transplantation, Autologous
D009842:Oligopeptides; D010455:Peptides; D000804:Angiotensin II; D002245:Carbon Dioxide; D003404:Creatinine; D001920:Bradykinin